olaparib,abiraterone
astrazeneca,merck
['abira', 'prostate', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'olaparib', 'propel', 'abiraterone']
#gu23 much awaited data from the ph3 propel shows continued rpfs benefits + strong trend for os (7 month) benefit with abiraterone + olaparib vs. abiraterone in 1st line mcrpc in hrr pos &amp; neg #prostatecancer #mediqgu23 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl19nxhM